Read by QxMD icon Read

Leukemia & Lymphoma

Zeba N Singh, Stephanie Richards, Firas El Chaer, Vu H Duong, Mary A Gudipati, Elizabeth O Waters, Sarah Koon, Matthew Webley, Beth Pitel, Nicole L Hoppman, Maria R Baer, Ying S Zou
No abstract text is available yet for this article.
July 11, 2018: Leukemia & Lymphoma
Tania Jain, Heidi E Kosiorek, Thomas E Grys, Shu Ting Kung, Vishal S Shah, Jeffrey A Betcher, James L Slack, Jose F Leis, Nandita Khera, Pierre Noel, Jeanne M Palmer, Lisa Z Sproat
Epstein-Barr virus (EBV) reactivation is an unresolved medical issue after allogeneic hematopoietic stem cell transplantation (HSCT). Rituximab treatment is recommended for EBV reactivation after HSCT but the number of doses of rituximab to use is unclear. In this study, risk factors and outcomes of patients who needed 1 dose vs >1 doses of preemptive rituximab to clear EBV viremia were compared. A higher viral load was more likely to be associated with higher doses of rituximab. Patients whose EBV viremia cleared with 1 dose of rituximab were more likely to have a preceding reduction of immunosuppression...
July 6, 2018: Leukemia & Lymphoma
Katherine L B Knorr, Martin S Tallman
No abstract text is available yet for this article.
July 6, 2018: Leukemia & Lymphoma
Tomasz Wróbel, Przemysław Biecek, Justyna Rybka, Anna Szulgo, Natalia Sorbotten, Agnieszka Giza, Agata Tyczyńska, Elżbieta Nowara, Agnieszka Badora-Rybicka, Krzysztof Adamowicz, Waldemar Kulikowski, Renata Kroll-Balcerzak, Andrzej Balcerzak, Wojciech Spychałowicz, Ewa Kalinka-Warzocha, Beata Kumiega, Joanna Drozd-Sokołowska, Edyta Subocz, Agata Sałek, Maciej Machaczka, Jadwiga Hołojda, Joanna Pogrzeba, Olga Dobrzyńska, Ewa Chmielowska, Wojciech Jurczak, Wanda Knopińska-Posłuszny, Krzysztof Leśniewski-Kmak, Jan Maciej Zaucha
We retrospectively analyzed long-term disease outcome of 350 elderly Hodgkin Lymphoma (eHL) patients treated with ABVD/ABVD-like regimen enrolled in the PLRG-R9 study between 2001 and 2013 in Poland. Complete remission was reported for 73% of early (ES) and 61% advanced stage (AS) patients. Nine (10%) ES and 56 (20%) AS patients have died. With the median follow-up of 36 (1-190) months, 3-year EFS and OS was 0.74 (95%CI: 0.63-0.85) and 0.90 (95%CI: 0.82-0.98) for ES; 0.51 (95%CI: 0.44-0.57), and 0.81 (95%CI: 0...
July 6, 2018: Leukemia & Lymphoma
Sung Won Lim, Kyung Ju Ryu, Hansang Lee, Young Hyeh Ko, Won Seog Kim, Seok Jin Kim
Extranodal natural killer/T-cell lymphoma (ENKTL) is associated with Epstein-Barr virus (EBV) infection, a common cause of hemophagocytosis. As interleukin-18 (IL18) is related with hemophagocytosis, we measured serum IL18 and IL18-related cytokines of newly diagnosed patients with ENKTL (N = 114) to investigate the role as a biomarker for hemophagocytosis and determine the prognosis of ENKTL. The median value of serum IL18 was 20.5 pg/mL (1.23-2021.81 pg/mL). The high IL18 group (≥20.5 pg/mL) was associated with stage III/IV, the presence of hemophagocytosis and poor treatment outcome...
July 6, 2018: Leukemia & Lymphoma
Alankrita Taneja, Jade Jones, Stefania Pittaluga, Irina Maric, Mohammed Farooqui, Inhye E Ahn, Adrian Wiestner, Clare Sun
No abstract text is available yet for this article.
July 6, 2018: Leukemia & Lymphoma
Azza M Kamel, Sally El-Fishawi, Eman O Rasekh, Eman R Radwan, Ashraf Zeidan, Abeer El-Said, Amen H Zaky, Maged Abdelfattah, Ahmed Refaat, Raafat Abdelfattah
Graft-versus-host disease (GVHD) remains one of the major complications of hematopoietic stem cell transplantation (HSCT). Several etiological factors were investigated. Among these, vitamin D and hence its receptor (VDR) gene polymorphisms have gained much interest; however, the results are still controversial. Using PCR-RFLP, we genotyped VDR polymorphisms FokI (rs10735810), ApaI (rs7975232), and Taq1 (rs731236) in 80 patient/donor pairs according to DNA availability. No association was encountered between VDR polymorphisms and GVHD...
July 4, 2018: Leukemia & Lymphoma
Diego Adrianzen Herrera, Sabarish Ayyappan, Sakshi Jasra, Noah Kornblum, Olga Derman, Aditi Shastri, Ioannis Mantzaris, Amit Verma, Ira Braunschweig, Murali Janakiram
Progressive multifocal leukoencephalopathy (PML) is a life-threatening opportunistic infection of immunomodulatory therapies. PML cases reported in PubMed (1995-2017) following stem-cell transplantation (HSCT) or chemoimmunotherapy (CIT) for hematologic malignancies were reviewed. We found 107 cases, 40% were HSCT recipients (32 allogeneic, 11 autologous) and 40% indolent lymphomas receiving monoclonal antibodies (mAbs). HSCT cases had longer time to PML diagnosis (10.8 vs. 4 months, p < .001), higher proportion of PML therapy response (58% vs...
July 3, 2018: Leukemia & Lymphoma
Yun-Ping Xu, Lotte Wieten, Song-Xing Wang, Yun Cai, Timo Olieslagers, Li Zhang, Liu-Mei He, Marce G J Tilanus, Wen-Xu Hong
Human leukocyte antigen (HLA)-E is a nonclassical HLA molecule with limited polymorphisms. Genotype frequency and expression of HLA-E were examined here for the first time in acute leukemia patients and healthy controls. The frequency of HLA-E*01:03/*01:03 individuals was significantly higher (p = .008, OR = 1.845), while the frequency of HLA-E*01:01/*01:01 individuals was much lower in the patient group (p = .002, OR = .363) than in control group. The surface expression on HLA-E*01:03/*01:03 individuals was found to be significantly higher than on HLA-E*01:01/*01:01 individuals in both of acute leukemia and control groups, but no significant difference was observed between the corresponding genotypes in two groups...
July 3, 2018: Leukemia & Lymphoma
Deepak Chellapandian, Jason D Pole, Paul C Nathan, Lillian Sung
The purpose was to describe the incidence and risk factors of congestive heart failure (CHF) among children with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). We included 2053 children (≤18 years) with first primary ALL and AML diagnosed 1992-2010 and registered in the Pediatric Oncology Group of Ontario Networked Information System. We identified CHF events through linked administrative databases. At 10 years, the cumulative incidence of CHF was 1.7% in ALL and 7.5% in AML. Factors associated with CHF in ALL were female gender, age <1 year at cancer diagnosis, irradiation and cumulative anthracycline dose ≥250 mg/m2 ...
July 3, 2018: Leukemia & Lymphoma
Ok-Kyong Chaekal, Koen van Besien
No abstract text is available yet for this article.
July 3, 2018: Leukemia & Lymphoma
Andrea Kaifie, Christian Schikowsky, Theresa Vasko, Thomas Kraus, Tim Henrik Brümmendorf, Patrick Ziegler
No abstract text is available yet for this article.
July 3, 2018: Leukemia & Lymphoma
Neel S Bhatt, Benjamin Oshrine, Julie An Talano
Hemophagocytic lymphohistiocytosis (HLH), a rare but life-threatening condition characterized by uncontrolled inflammation, is increasingly recognized in adults. The management of adult onset HLH is challenging, in part due to gaps in current state of knowledge on etiology, clinical presentation, diagnosis, and management. HLH secondary to triggers such as infections, autoimmune disorders, and malignancy are more commonly seen in adults although cases of familial form have also been reported. Underlying conditions such as sepsis, or malignancy could pose as major confounders while applying universal diagnostic criteria, and therefore could lead to delay in diagnosis...
July 3, 2018: Leukemia & Lymphoma
Domenico Albano, Giovanni Bosio, Alessandro Re, Chiara Pagani, Raffaele Giubbini, Francesco Bertagna
Burkitt's lymphoma is a lymphoma with unclear metabolic behavior at 18F-FDG-PET/CT and no validated criteria in treatment evaluation and prediction of outcome exist. Sixty-five patients were retrospectively included: all underwent baseline 18F-FDG-PET/CT, 56 interim PET/CT (iPET/CT) and 54 end of treatment PET/CT (eotPET/CT) after chemotherapy. Interim and eotPET/CT results were visually interpreted according to the criteria of the IHP and Deauville-five-point-scale. Results were correlated with PFS and OS to assess and to compare the predictive value of iPET and eotPET according to each criterion...
July 3, 2018: Leukemia & Lymphoma
Paolo Strati, William F Glass, Maen Abdelrahim, Umut Selamet, Amanda Tchakarov, Biruh T Workeneh, Srdan Verstovsek, Ala Abudayyeh
No abstract text is available yet for this article.
July 3, 2018: Leukemia & Lymphoma
M Kathiravan, Minu Singh, Prateek Bhatia, Amita Trehan, Neelam Varma, Manupdesh Singh Sachdeva, Deepak Bansal, Richa Jain, Shano Naseem
Considering conflicting data on CDKN2A/B deletion in ALL, this study to assess its prognostic significance as an independent marker in a total of 96 pediatric B and T-ALL cases was planned. The overall frequency of CDKN2A/B deletion was 44% (n = 43) with 36% (30/83) in B-ALL and 100% (13/13) in T-ALL. CDKN2A/B deletion was significantly associated with high WBC count (p = .002) and National Cancer Institute risk (p = .01) in B-ALL. Importantly, CDKN2A/B deletion cases had poor EFS of 42% at 28 months compared to EFS of 90% in rest (p = ...
July 3, 2018: Leukemia & Lymphoma
Charalampos Pontikoglou, Athanasia Kalyva, Christina Kalpadakis, Maria Velegraki, Nikoletta Bizymi, Kalliopi Alpantaki, George Kontakis, Gerassimos A Pangalis, Helen A Papadaki
No abstract text is available yet for this article.
July 3, 2018: Leukemia & Lymphoma
Thomas A Ollila, Adam J Olszewski
No abstract text is available yet for this article.
July 3, 2018: Leukemia & Lymphoma
Mita Manna, Richard Lee-Ying, Gwynivere Davies, Colin Stewart, Danielle H Oh, Anthea Peters, Douglas A Stewart
Although chemoimmunotherapy improves outcomes for patients with follicular lymphoma (FL), approximately 20% of patients experience early disease progression within two years of treatment and subsequently poor median survival. We conducted a retrospective study to evaluate survival rates of patients with early relapse who were treated with or without autologous transplantation. Of 517 patients with FL and who received chemoimmunotherapy, 152 relapsed and survived a minimum of four months after progression, including 84 (55...
July 3, 2018: Leukemia & Lymphoma
Samuel Romero, Juan Montoro, Marta Guinot, Luis Almenar, Rafael Andreu, Aitana Balaguer, Isabel Beneyto, Jordi Espí, José Gómez-Codina, Gloria Iacoboni, Isidro Jarque, Rafael López-Andújar, Empar Mayordomo-Aranda, Joaquín Montalar, Amparo Pastor, Miguel Pastor, José L Piñana, Nohelia Rojas-Ferrer, Ignacio Sánchez-Lázaro, Jesús Sandoval, Guillermo Sanz, Miguel Á Sanz, Amparo Solé, Jaime Sanz
Post-transplant lymphoproliferative disorders (PTLD) are a rare complication after both solid organ (SOT) and allogeneic hematopoietic stem cell transplantation (allo-HSCT). In this single center retrospective study, we compared clinical, biological, and histological features, and outcomes of PTLD after both types of transplant. We identified 82 PTLD (61 after SOT and 21 after allo-HSCT). The presence of B symptoms, Waldeyer ring, spleen, central nervous system, and liver involvement, and advanced Ann-Arbor stage were more frequent in allo-HSCT recipients...
July 3, 2018: Leukemia & Lymphoma
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"